This PDF is the current document as it appeared on Public Inspection on 01/10/2014 at 08:45 am.
Department of the Army, DoD.
Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/851,573, entitled “Contact Pathway and Tissue Kallikrein Inhibitors can Prevent/Reduce Leakage Caused by Hantavirus,” filed on March 15, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.Start Further Info
FOR FURTHER INFORMATION CONTACT:
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619-6664, both at telefax (301) 619-5034.End Further Info End Preamble Start Supplemental Information
The invention relates to treatment of vascular leakage symptoms infected with the Hantavirus using drugs that are already FDA approved.Start Signature
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2014-00285 Filed 1-10-14; 8:45 am]
BILLING CODE 3710-08-P